Allarity Therapeutics
Allarity Therapeutics develops stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer in clinical stage.
8-KNov 17Latest SEC filing
Nov 16Latest story
November 2026
October 2026
August 2026
Allarity Therapeutics develops stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer in clinical stage.
November 2026
October 2026
August 2026